Healthcare
Silence Therapeutics plc(SLN)
Live Price
Offline$6.69
+0.15% today
1Y Change
+13.61%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $340.00M
- Revenue Growth
- -98.7%
- EPS Growth
- +20.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Silence Therapeutics plc (SLN) is a Healthcare stock with a market cap of $340.00M and listed on NASDAQ. The stock last traded around $6.69 and up 13.6% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -98.7%, EPS growth of +20.3%, a dividend yield of 0.0%. What stands out right now is revenue -98.7%, EPS +20.3%, free cash flow +8.1% with operating margin -16292.8% and ROIC -77.3%. Valuation already assumes a fairly strong business story at price/sales 602.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SLN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-98.7% vs +7.6% peer median
Operating Margin
Below sector median
-16292.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 7, 2026 with an EPS surprise of +3.0% and a revenue surprise of -66.4%.
The operating picture looks softer than before
Revenue is at -98.7% and EPS is at +20.3%, with operating margin around -16292.8%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +14.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | +3.0% | +0.3% | +2.6% | -11.2% |
2026 Mar 5, 2026 | +21.9% | +13.3% | +26.7% | +8.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SLN Max Drawdown
-41.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SLN and SPY.
Company Overview
Silence Therapeutics plc
NASDAQ Global Market
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
- Leadership
- Iain Gladstone Ross
- IPO Date
- Sep 8, 2020
- Employees
- 116
- Street Address
- 72 Hammersmith Road
- Mailing
- London, W14 8TH
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 3457 6900
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 602.5
- Price/Book
- 5.4
Growth
- Revenue
- -98.7%
- EPS
- +20.3%
- Free Cash Flow
- +8.1%
Profitability
- Gross Margin
- 61.5%
- Operating Margin
- -16292.8%
- Net Margin
- -15851.9%
- ROE
- -300.9%
- ROIC
- -77.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 8.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.